- Conditions
- Treatment Resistant Depression
- Interventions
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Depression clinical trials
Directory of U.S. ClinicalTrials.gov public records for Depression. Browse Depression recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 22, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
How Depression studies are organized in the registry
Most records use the formal term “major depressive disorder” or MDD rather than “depression” alone, and “treatment-resistant depression” (TRD) labels a distinct, sizable subset. The portfolio includes many behavioral, digital, and device interventions, so the intervention and study-type filters do real work here.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms, Occupational Burnout
- Interventions
- Neuralli Mood
- Dietary Supplement
- Lead sponsor
- Efforia, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment-Resistant Depression
- Interventions
- NRX-101, Transcranial Magnetic Stimulation Sham
- Drug · Device
- Lead sponsor
- NeuroRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- Interventions
- ACP-211, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Chino, California • Glendale, California + 19 more
- Conditions
- Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
- Interventions
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Device
- Lead sponsor
- Nader Pouratian
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Depression
- Interventions
- Vagus Nerve Stimulation, Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
- Interventions
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Treatment Resistant Major Depressive Disorder
- Interventions
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
- Conditions
- Healthy, Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- Ketamine, Saline
- Drug · Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
About this Depression clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Depression as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Depression.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Depression.